Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Immunotherapy, Tumor Microenvironment and Survival Signaling
| Immunotherapy, Tumor Microenvironment and Survival Signaling |
| Autore | Golubovskaya Vita |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 online resource (376 p.) |
| Soggetto topico |
Clinical and internal medicine
Medicine and Nursing |
| Soggetto non controllato |
angiogenesis
antigen loss Autophagy BCMA breast cancer cancer cancer immunotherapy cancer metabolism cancer nanomedicine cancer stem cells cancer vaccines CAR macrophage CAR T cell CAR-T CAR-T cells cardiotoxicity CD11 CD18 CD19 CD37 cell therapy cell-cell contact check point inhibitors checkpoint chemotherapy chimeric antigen receptor chimeric antigen receptors clonogenicity colorectal cancer combination therapy crosstalk DCLK1 dendritic cells electroporation hypoxia immune checkpoint inhibitor immune checkpoint inhibitors immune escape immunogenic cell death immunometabolism immunomodulation immunomodulators immunotherapeutic agent immunotherapies immunotherapy lentiviral transduction lentivirus leukemia cells lung metastasis lymphoma lytic peptides macrophages melanoma microenvironment miRNA mitochondria mitochondrial transfer myeloid-derived suppressor cells n/a nanoparticles oncolytic viral therapy pathogenesis pediatric solid tumors personalized medicine programmed cell death 1 ligand 1 programmed cell death protein 1 regulatory T cells resistance risk factors solid tumors targeted therapy targeted treatment triple-negative breast cancer tuft cells tumor tumor antigen tumor antigens tumor immune evasion tumor microenvironment tumor stem cells tumor stroma tunneling nanotubes tyrosine kinase inhibitors β2 integrins |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910580205403321 |
Golubovskaya Vita
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Monoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy
| Monoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy |
| Autore | Ruvo Menotti |
| Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
| Descrizione fisica | 1 online resource (278 p.) |
| Soggetto topico | Technology: general issues |
| Soggetto non controllato |
adoptive immunotherapy
affibody molecules affinity aggregation AL amyloidosis amyloid anti-CD38 MoAb antibody antibody fragment antibody fragments Antibody-Drug Conjugate antibody-drug conjugates BCMA belantamab mafodotin bispecific bispecific T-cell engager blood-brain barrier cancer therapy CAR adaptor CD38 cDNA CHI3L1 chimeric antigen receptor (CAR T) chimeric antigen receptor T-cells cross-linking Daratumumab developability drug targeting E. coli Fab glutamate carboxypeptidase II guinea pig idecabtagene vicleucel immunization immunogenicity in vivo imaging Isatuximab JNJ-68284528 lung metastasis Mabs modular CAR T monoclonal antibodies monoclonal antibody myeloma NAALADase neurodegenerative disorders neurotoxicity non-specific binding nucleocapsid NUsc1 oligomer payload phage display pharmacokinetics polyspecificity porcine deltacoronavirus prostate cancer prostate-specific membrane antigen protein engineering protocol receptor-mediated transcytosis scFv self-association single chain solubility specificity split CAR stability transferrin receptor universal CAR T universal immune receptor viscosity YKL-40 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557613003321 |
|
Ruvo Menotti
|
||
| Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||